Logo

Boehringer Ingelheim and Lilly Collaborate with DCRI for Evaluating Jardiance (empagliflozin) in a Pragmatic EMPACT-MI Study

Share this

Boehringer Ingelheim and Lilly Collaborate with DCRI for Evaluating Jardiance (empagliflozin) in a Pragmatic EMPACT-MI Study

Shots:

  • The collaboration will evaluate whether Jardiance can improve outcomes and prevent heart failure in adults with/ out diabetes who had an acute MI. The study assesses the efficacy of Jardiance vs PBO in adults hospitalized with an acute myocardial infarction
  • The EMPACT-MI study is a part of EMPOWER clinical trial program and includes ~3-300 patients with acute MI across 16 countries with the 1EPs as the effect of Jardiance on all-cause mortality and hospitalization for HF
  • The collaboration will leverage the DCRI's experience in pragmatic trials by implementing innovative trial elements- including remote follow-up and a focused data collection approach- which enable a strong patient focus while maintaining high data quality

Click here ­to­ read full press release/ article | Ref:  Eli Lilly | Image: StraitTimes

Related News: Boehringer Ingelheim and Lilly Commence P-III EMPULSE Study to Evaluate Jardiance in People Hospitalized for Acute Heart Failure Who Have Been Stabilized


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions